We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis. Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq:...
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast’s time to Phase 3 data Upsized Oxford Finance debt...
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549__________________________________________FORM S-8REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF...
0001746473FALSE00017464732024-02-272024-02-27 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549__________________________________________FORM...
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH SAN...
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.3 | -1.97368421053 | 15.2 | 15.63 | 14.07 | 326925 | 14.60309331 | CS |
4 | -2.19 | -12.8145114102 | 17.09 | 17.585 | 14.07 | 361378 | 15.14131868 | CS |
12 | -3.5 | -19.0217391304 | 18.4 | 19.62 | 13.4 | 407366 | 16.42675997 | CS |
26 | -1.74 | -10.4567307692 | 16.64 | 19.62 | 12.605 | 457489 | 15.86274 | CS |
52 | -11.62 | -43.8159879336 | 26.52 | 30.85 | 12.605 | 625096 | 19.00235273 | CS |
156 | -24.54 | -62.2210953347 | 39.44 | 40 | 3.965 | 545354 | 20.74081474 | CS |
260 | -7.6 | -33.7777777778 | 22.5 | 43.92 | 3.965 | 457757 | 21.28753312 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions